Rare Diseases

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

On September 5th, 2024, Katherine Scott and Lana Duan from MORSE Consulting presented “Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies” at the CDA-AMC Symposium. They explored how pre-NOC submissions impact market access timelines, using CDA-validated data and insights from our internal database.Download our presentation to learn more about these findings and strategies for accelerating access to new therapies. Panelists We'd like to thank all…

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

MORSE's Sang Mi Lee joins a podcast with Exactis Innovation discussing the intricacies of Canada's drug reimbursement system and how it might evolve with the recent creation of the Canadian Drug Agency (CDA).   Summary: With national pharmacare closer to reality in Canada, our insightful conversation with market access professionals and seasoned pharmacists, Sang Mi Lee, MBA, BSc Phm, RPh and Brian O’Rourke, sheds light on the intricacies of Canada’s drug reimbursement system…

At MORSE Consulting, we're delighted to share insights from Sherry O'Quinn's recent participation at the Rare Disease Day 2024 Summit held by the Canadian Organization for Rare Disorders (CORD) in Ottawa. The conference, themed around sustaining the momentum of two decades of impactful work in the rare disease community, was insightful and inspiring.   Sherry had the opportunity to present a snapshot on the timelines to access for drugs for…

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.